Send us Feedback

OraSure Technologies (OSUR)
Analysis
SUMMARY
BULLS
BEARS
TOPICS
Data
DATA CENTRAL
STOCK CHART
Financials
SEC FILINGS
BALANCE
INCOME
CASH FLOW
QUOTE AND NEWS
OraSure Technologies Earnings Conference Call Invitation
Globe Newswire  Jan 28  Comment 
BETHLEHEM, Pa., Jan. 28, 2010 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) has scheduled its regular earnings conference call covering 2009 fourth quarter and full‑year financial results and certain 2010 financial guidance for 5:00
OraSure Technologies and Roche Diagnostics Sign Worldwide Commercialization Agreement for Fully Automated Oral Fluid Drugs of Abuse Assays
Globe Newswire  Jan 19  Comment 
BETHLEHEM, Pa., Jan. 19, 2010 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) and Roche Diagnostics today announced that the companies have signed an agreement for the worldwide commercialization of homogeneous fully automated oral fluid
OraSure Tech (OSUR) Files Additional Data with U.S. FDA for OraQuick
StreetInsider.com  Jan 7  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/OraSure+Tech+%28OSUR%29+Files+Additional+Data+with+U.S.+FDA+for+OraQuick/5229414.html for the full story.
OraSure Technologies Files Additional Data With FDA in Support of PMA Application for OraQuick Rapid HCV Test
Globe Newswire  Jan 7  Comment 
OraSure Technologies to Participate at the Twelfth Annual Needham Growth Conference
Globe Newswire  Jan 5  Comment 
BETHLEHEM, Pa., Jan. 5, 2010 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that Douglas A. Michels, President and Chief Executive Officer, will speak to the investment community at the Twelfth Annual Needham Growth
Photo Release -- OraSure Technologies Receives CE Mark for OraQuick(R) Rapid HCV Antibody Test
Globe Newswire  Dec 15  Comment 
BETHLEHEM, Pa., Dec. 15, 2009 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) announced today that it has received approval to affix the CE mark to its OraQuick(R) Rapid HCV Antibody Test. A CE mark is required to sell this test in the
OraSure (OSUR) Receives Approval to Label OraQuick Rapid HCV Antibody Test with CE Mark
StreetInsider.com  Dec 15  Comment 
OraSure Technologies Announces Settlement of Patent Infringement Lawsuit With Inverness and Church & Dwight
Globe Newswire  Nov 19  Comment 
BETHLEHEM, Pa., Nov. 19, 2009 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced the settlement of the patent infringement lawsuit filed against OraSure by Inverness Medical Innovations, Inc. (NYSE:IMA), Inverness Medical
OraSure Tech (OSUR) Settles Patent Infringement Suit with Inverness (IMA), Inverness Switzerland, and Church & Dwight (CHD)
StreetInsider.com  Nov 19  Comment 
OraSure Technologies Participates in BPAC Meeting on HIV Over-the-Counter Test
Globe Newswire  Nov 18  Comment 
BETHLEHEM, Pa., Nov. 18, 2009 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) today announced that it participated in a Blood Products Advisory Committee ("BPAC") meeting held November 17, 2009 in which the BPAC considered, among other
Needham & Co Upgrades OraSure Technologies (OSUR) to Buy
StreetInsider.com  Nov 17  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Upgrades/Needham+%26+Co+Upgrades+OraSure+Technologies+%28OSUR%29+to+Buy/5117840.html for the full story.
OraSure Technologies (OSUR) Tops Q3 EPS by 9c; Mixed Guidance
StreetInsider.com  Nov 4  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Earnings/OraSure+Technologies+%28OSUR%29+Tops+Q3+EPS+by+9c%3B+Mixed+Guidance/5075791.html for the full story.
OraSure Announces 2009 Third Quarter Financial Results
Globe Newswire  Nov 4  Comment 
BETHLEHEM, Pa., Nov. 4, 2009 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR), a market leader in oral fluid diagnostics, today announced revenues of $21.6 million for the three months ended September 30, 2009, compared to $16.9 million



Thank you for your suggestion
SEC FILINGS
SEC FILINGS  (See all)
10-K (Mar 09)
Older: 03/12/08, 03/16/07, 03/15/06, 03/15/05
10-Q (Nov 09)
Older: 08/06/09, 05/07/09, 11/06/08, 08/06/08
View All Filings for OraSure_Technologies (OSUR)
more ▼WIKI ANALYSIS
 
TOP CONTRIBUTORS
Associate
Chris Morrissey
OSUR AT A GLANCE
P/E ►-4.69 
EV/EBITDA ►-32.1 
ROA ►-23.7% 
ROE ►-28.1% 
Debt to Equity ►0.207 
Current Ratio ►7.60 
Interest Coverage Ratio ►-37.7 
 
 
Please install Flash Player to view this chart.
 
 
 
Please install Flash Player to view this chart.
 

OraSure Technologies develops, manufactures and markets oral fluid specimen collection devices using proprietary oral fluid technologies, diagnostic products including immunoassays and other in vitro diagnostic tests, and other medical devices. These products are sold in the United States as well as internationally to various clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians’ offices, and commercial and industrial entities.

OraSure Technologies is the leading supplier of oral-fluid collection devices and in vitro diagnostic assays to the employment, criminal justice, drug treatment, life insurance and public health markets for the detection of abused drugs and the antibodies to HIV. Based in Bethlehem, Pennsylvania, the Company develops, manufactures and markets oral specimen collection devices, in vitro diagnostic tests, and other medical devices.




References

Retrieved from "http://www.wikinvest.com/stock/OraSure_Technologies_(OSUR)"
Wikinvest © 2006, 2007, 2008, 2009, 2010. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki